Search
Infigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawncholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. … [A235174] On May 28, 2021, the FDA granted accelerated approval to infigratinib - under the market name Truseltiq - for the treatment of previously treated, unresectable locally advanced or metastatic
Clavulanic acid
go.drugbank.com/drugs/DB00766ApprovedInvestigationalVet approvedClavulanic acid is a beta-lactamase inhibitor that is frequently combined with Amoxicillin or Ticarcillin to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible ...
Mixtures: Amoxicillin/Clavulansäure Astro 500 mg/100 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung, Amoxicillin/Clavulansäure Astro 1000 mg/200 mg Pulver zur Herstellung einer Injektions- oder InfusionslösungPiflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalIt was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.
Doripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnDoripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. … The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.
Gepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients. … [L52680,L52685] In December later the same year, the FDA approved another indication for gepotidacin for the treatment of uncomplicated urogenital gonorrhea. [L54803]
Tocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385]. … [L40164] Subsequently, it was granted approval by Health Canada and the FDA in October [L43697] and December 2022, respectively.
Afimoxifene
go.drugbank.com/drugs/DB04468InvestigationalAfimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia. TamoGel is formulated using Enhanced Hydr...
Istisociclib
go.drugbank.com/drugs/DB21703InvestigationalIstisociclib is under investigation in clinical trial NCT04718675 (A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer
Etonogestrel
go.drugbank.com/drugs/DB00294ApprovedInvestigational[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]
Tetradecyl hydrogen sulfate (ester)
go.drugbank.com/drugs/DB11328ApprovedSodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose veins . Sodiu...